Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
OPHT's Cash-to-Debt is ranked higher than
73% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. OPHT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OPHT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset -0.32
OPHT's Equity-to-Asset is ranked lower than
95% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. OPHT: -0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
OPHT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.14 Max: 0.27
Current: -0.32
-0.32
0.27
Interest Coverage No Debt
OPHT's Interest Coverage is ranked higher than
68% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPHT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OPHT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -3.64
Beneish M-Score: -4.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -384.14
OPHT's Operating Margin % is ranked lower than
66% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. OPHT: -384.14 )
Ranked among companies with meaningful Operating Margin % only.
OPHT' s Operating Margin % Range Over the Past 10 Years
Min: -384.14  Med: -239.84 Max: -195.14
Current: -384.14
-384.14
-195.14
Net Margin % -379.93
OPHT's Net Margin % is ranked lower than
66% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. OPHT: -379.93 )
Ranked among companies with meaningful Net Margin % only.
OPHT' s Net Margin % Range Over the Past 10 Years
Min: -379.93  Med: -283.02 Max: -205.26
Current: -379.93
-379.93
-205.26
ROA % -51.89
OPHT's ROA % is ranked lower than
66% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. OPHT: -51.89 )
Ranked among companies with meaningful ROA % only.
OPHT' s ROA % Range Over the Past 10 Years
Min: -241.11  Med: -49.53 Max: -23.27
Current: -51.89
-241.11
-23.27
ROC (Joel Greenblatt) % -2583.68
OPHT's ROC (Joel Greenblatt) % is ranked lower than
72% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. OPHT: -2583.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OPHT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -26895.89  Med: -12055.47 Max: -2583.68
Current: -2583.68
-26895.89
-2583.68
3-Year EBITDA Growth Rate 1.40
OPHT's 3-Year EBITDA Growth Rate is ranked lower than
51% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. OPHT: 1.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OPHT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -44.4  Med: -27.7 Max: 1.4
Current: 1.4
-44.4
1.4
3-Year EPS without NRI Growth Rate -4.90
OPHT's 3-Year EPS without NRI Growth Rate is ranked lower than
53% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. OPHT: -4.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OPHT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.3  Med: -41 Max: -4.9
Current: -4.9
-42.3
-4.9
GuruFocus has detected 4 Warning Signs with Ophthotech Corp $OPHT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPHT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OPHT Guru Trades in Q1 2016

Paul Tudor Jones 11,296 sh (New)
Steven Cohen 414,400 sh (New)
Jim Simons 362,500 sh (+20.27%)
Eaton Vance Worldwide Health Sciences Fund 331,000 sh (unchged)
Pioneer Investments 64,092 sh (-22.94%)
» More
Q2 2016

OPHT Guru Trades in Q2 2016

Eaton Vance Worldwide Health Sciences Fund 331,000 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
Pioneer Investments 63,987 sh (-0.16%)
Paul Tudor Jones 10,501 sh (-7.04%)
» More
Q3 2016

OPHT Guru Trades in Q3 2016

Steven Cohen 786,300 sh (New)
Pioneer Investments 86,992 sh (+35.95%)
Paul Tudor Jones 7,094 sh (-32.44%)
Eaton Vance Worldwide Health Sciences Fund 284,600 sh (-14.02%)
» More
Q4 2016

OPHT Guru Trades in Q4 2016

Paul Tudor Jones 67,023 sh (+844.78%)
Steven Cohen Sold Out
Pioneer Investments Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OPHT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:NVIV, OTCPK:BNOEF, NAS:MDWD, NAS:LPTX, OTCPK:CTIX, NAS:AQB, NAS:ATHX, NAS:AGTC, NAS:EVGN, NAS:MRTX, NAS:VVUS, NAS:CNAT, OTCPK:RNUGF, NAS:CDTX, OTCPK:TBGNF, NAS:PSTI, NAS:EGLT, NAS:ZFGN, NAS:CTIC, NAS:ALBO » details
Traded in other countries:O2T.Germany,
Ophthotech Corp is a biopharmaceutical company. The Company is engaged in the development of novel therapeutics to treat diseases of the back of the eye, developing therapeutics for age-related macular degeneration.

Top Ranked Articles about Ophthotech Corp

Steven Cohen Adds to Fairmount Santrol, Ophthotech Guru increases his positions in energy company, biopharmaceutical company
Steven Cohen (Trades, Portfolio), founder and CEO of Point72 Asset Management, increased his position in two holdings recently. He increased his holding in Fairmount Santrol Holdings Inc. (NYSE:FMSA) by 21.2% on Dec. 7 and increased his position in Ophthotech Corp. (NASDAQ:OPHT) by 128.9% on Dec. 8. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 2.62
OPHT's Forward PE Ratio is ranked higher than
96% of the 78 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. OPHT: 2.62 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PS Ratio 2.44
OPHT's PS Ratio is ranked higher than
85% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. OPHT: 2.44 )
Ranked among companies with meaningful PS Ratio only.
OPHT' s PS Ratio Range Over the Past 10 Years
Min: 2.26  Med: 34.7 Max: 70.15
Current: 2.44
2.26
70.15
EV-to-EBIT 0.80
OPHT's EV-to-EBIT is ranked higher than
83% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. OPHT: 0.80 )
Ranked among companies with meaningful EV-to-EBIT only.
OPHT' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.3  Med: -12.7 Max: 0.85
Current: 0.8
-37.3
0.85
EV-to-EBITDA 0.81
OPHT's EV-to-EBITDA is ranked higher than
85% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. OPHT: 0.81 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPHT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.7  Med: -12.7 Max: 0.86
Current: 0.81
-37.7
0.86
Current Ratio 4.49
OPHT's Current Ratio is ranked higher than
54% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. OPHT: 4.49 )
Ranked among companies with meaningful Current Ratio only.
OPHT' s Current Ratio Range Over the Past 10 Years
Min: 0.34  Med: 6.33 Max: 34.54
Current: 4.49
0.34
34.54
Quick Ratio 4.49
OPHT's Quick Ratio is ranked higher than
56% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. OPHT: 4.49 )
Ranked among companies with meaningful Quick Ratio only.
OPHT' s Quick Ratio Range Over the Past 10 Years
Min: 0.34  Med: 6.33 Max: 34.54
Current: 4.49
0.34
34.54
Days Sales Outstanding 25.32
OPHT's Days Sales Outstanding is ranked higher than
78% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. OPHT: 25.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPHT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.49  Med: 25.32 Max: 31.1
Current: 25.32
8.49
31.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.40
OPHT's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. OPHT: -4.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPHT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -190  Med: -189.4 Max: -4.4
Current: -4.4
-190
-4.4

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.07
OPHT's Price-to-Median-PS-Value is ranked higher than
98% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. OPHT: 0.07 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPHT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 1.09 Max: 1.54
Current: 0.07
0.07
1.54
Earnings Yield (Greenblatt) % 119.92
OPHT's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. OPHT: 119.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPHT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 113.25  Med: 155.15 Max: 186.1
Current: 119.92
113.25
186.1

More Statistics

Revenue (TTM) (Mil) $50.91
EPS (TTM) $ -5.45
Beta1.92
Short Percentage of Float23.44%
52-Week Range $3.24 - 65.96
Shares Outstanding (Mil)35.81

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) 1.35 -1.65 -1.50
EPS without NRI ($) 1.35 -1.65 -1.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OPHT

Headlines

Articles On GuruFocus.com
Steven Cohen Adds to Fairmount Santrol, Ophthotech Dec 16 2016 
Largest Insiders' Trades of the Week May 27 2016 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Weekly 3-Year Low Highlight: VIV, CNHI, WTW, OPHT Nov 17 2013 
Insiders Are Buying Ophthotech Oct 08 2013 

More From Other Websites
Ophthotech Corp. :OPHT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Ophthotech Corp. :OPHT-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
OPHTHOTECH 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General... Mar 10 2017
EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ophthotech Corporation... Mar 09 2017
INVESTOR COMPLAINT: Levi & Korsinsky, LLP Reminds Investors of Ophthotech Corporation of a Class... Mar 08 2017
OPHTHOTECH CORP. Financials Mar 07 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ophthotech... Mar 07 2017
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 07 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Ophthotech... Mar 06 2017
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ophthotech... Mar 06 2017
OPHTHOTECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS... Mar 03 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of... Mar 03 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Mar 03 2017
SHAREHOLDER COMPLAINT: Levi & Korsinsky, LLP Reminds Investors of Ophthotech Corporation of a Class... Mar 03 2017
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action... Mar 03 2017
Are Options Traders Betting on a Big Move in Ophthotech (OPHT) Stock? Mar 03 2017
Ophthotech Hits 52-Week Low on 4Q Loss, Updates Mar 01 2017
Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss Mar 01 2017
Ophthotech reports 4Q loss Feb 28 2017
Ophthotech reports 4Q loss Feb 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)